BRTX · XBRL financial data
BioRestorative Therapies financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BRTX's year ends in late December)
| In millions of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of goods and services sold | — | — | — | — | 0 | 0 |
| Gross profit | — | — | — | 0 | 0 | 0 |
| Research and development | 1 | 1 | 4 | 4 | 5 | 10 |
| General and administrative | 2 | 26 | 16 | 11 | 7 | 6 |
| Total operating expenses | 3 | 26 | 19 | 15 | 12 | 16 |
| Operating income (loss) | (3) | (26) | (19) | (15) | (12) | (16) |
| Other income (expense) | — | — | 0 | 0 | 0 | 0 |
| Net income (loss) | (11) | (44) | (18) | (10) | (9) | (14) |
| Earnings per share, basic USD per share | — | (37.30) | (5.11) | (2.47) | (1.16) | (1.58) |
| Earnings per share, diluted USD per share | — | — | (3.65) | (2.47) | (1.16) | (1.58) |
| Weighted average shares, basic millions of shares | — | 1 | 4 | 4 | 8 | 9 |
| Weighted average shares, diluted millions of shares | — | — | 4 | 4 | 8 | 9 |
- † Share count changed about 1/876 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (BRTX's year ends in late December)
| In millions of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 21 | 2 | 1 | 1 | 2 |
| Marketable securities | — | — | 13 | 10 | 10 | 1 |
| Accounts receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Prepaid and other current assets | — | 0 | 0 | 0 | 0 | 0 |
| Total current assets | 3 | 21 | 15 | 11 | 11 | 3 |
| Property and equipment, net | 0 | 0 | 0 | 0 | 0 | 0 |
| Right-of-use asset | 0 | 0 | 0 | 0 | — | — |
| Total assets | 4 | 22 | 16 | 13 | 12 | 4 |
| Accounts payable | 0 | 0 | 0 | 0 | 0 | 1 |
| Accrued liabilities | 1 | 0 | 0 | 1 | 1 | — |
| Total current liabilities | 1 | 0 | 0 | 3 | 4 | 4 |
| Lease liability, non-current | 0 | 0 | 0 | — | — | — |
| Total liabilities | 6 | 1 | 1 | 3 | 4 | — |
| Accumulated deficit | (90) | (134) | (153) | (147) | (156) | (170) |
| Total stockholders' equity | (1) | 22 | 16 | 10 | 9 | 0 |
| Total liabilities and equity | 4 | 22 | 16 | 13 | 12 | 4 |
| Common shares outstanding (cover page) millions of shares | 3,176 | 4 | 4 | 7 | 8 | 25 |
- † Share count changed about 1/876 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (BRTX's year ends in late December)
| In millions of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (11) | (44) | (18) | (10) | (9) | (14) |
| Stock-based compensation | 1 | 23 | 13 | 8 | 3 | 3 |
| Depreciation and amortization | 0 | 0 | 0 | — | — | — |
| Net cash from operating activities | (2) | (3) | (6) | (6) | (8) | (11) |
| Purchases of property and equipment | — | 0 | 0 | 0 | 0 | 0 |
| Net cash from investing activities | — | (0) | (13) | 3 | 1 | 9 |
| Proceeds from issuing common stock | — | — | — | 2 | — | 3 |
| Proceeds from issuing equity | 0 | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | 0 |
| Net cash from financing activities | 6 | 21 | — | 2 | 7 | 3 |
| Net change in cash | 3 | 18 | (19) | (1) | (0) | 1 |
- † Share count changed about 1/876 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 8090 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8090 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| BioRestorative Therapies | 3.1 | 0 | (3.8) | 25.5M | 0.9 quarters | 10-QMar 31, 2026 |
| IMAC Holdings | 0 | 0 | (1.4)* | 3.8M | 0.0 quarters | 10-QSep 30, 2025 |
| Marpai | 0.1 | 4.2 | (4.1)* | 26.8M | 0.0 quarters | 10-QJun 30, 2026 |
| Mangoceuticals | 0.2 | 0.1 | (0.3)* | 21.6M | 0.9 quarters | 10-QJun 30, 2026 |
| Elite Health Systems | 1.3 | 1.3 | (1.4)* | 28.5M | 1.0 quarters | 10-QJun 30, 2026 |
| Cryo Cell International | 1.4 | 7.8 | 1.1* | 8.1M | — | 10-QAug 31, 2026 |
| Pacific Health Care Organization | 2.7 | 1.5 | 0.5* | 12.8M | — | 10-QSep 30, 2026 |
| BioCorRx | 0 | 0.1 | (0.4)* | 29.8M | 0.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.